Wird geladen...
Belimumab for systemic lupus erythematosus
BACKGROUND: Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity. OBJECTIVES: To assess the benefits and harms of belimumab (alone or in combination) in system...
Gespeichert in:
| Veröffentlicht in: | Cochrane Database Syst Rev |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley & Sons, Ltd
2021
|
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8095005/ https://ncbi.nlm.nih.gov/pubmed/33631841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010668.pub2 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|